Want to see LFWD full AI Analyst Report?
LFWD Stock Chart & Stats
$6.79
-$0.33(-14.93%)
At close: 4:00 PM EST
$6.79
-$0.33(-14.93%)
Day’s Range― - ―
52-Week Range$4.14 - $10.98
Previous CloseN/A
Volume483.00K
Average Volume (3M)316.99K
Market Cap
$21.64M
Enterprise Value$8.64M
Total Cash (Recent Filing)$11.42M
Total Debt (Recent Filing)$8.81M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 12, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.66
Shares Outstanding2,814,409
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue0.41
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$10.00Price Target Upside47.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$28.29M
Bulls Say, Bears Say
Bulls Say
Improved Liquidity Via FinancingA meaningful cash infusion materially reduces near-term liquidity risk and gives management runway to complete the manufacturing transition, fund working capital and pursue commercialization initiatives. This stronger liquidity profile lowers the probability of imminent distress and supports execution toward profitability in 2026–2027.
ReWalk Revenue And Reimbursement ExpansionProduct-level revenue growth alongside reimbursement and distribution gains signals improving product-market fit and lower adoption friction. Durable reimbursement access and expanding channels increase addressable market, recurring service opportunities and the potential for steadier, higher-margin sales as scale and coverage broaden over months.
Strengthened Clinical LeadershipAdding an experienced CMO enhances clinical credibility, trial design and payer engagement — vital for neurorehabilitation adoption and reimbursement. Strong medical leadership supports long-term partnerships with clinicians and rehab centers, improving evidence generation and adoption pathways over multiple quarters.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow means the business cannot self-finance growth or transitions, raising ongoing dependence on external funding. Over months this elevates dilution and liquidity risk, constrains strategic flexibility and pressures management to prioritize near-term stabilization over long-term investments.
Weak Equity CushionA reported zero equity base materially reduces the balance-sheet buffer against future losses and limits borrowing capacity. If operating losses persist, the company faces heightened insolvency, refinancing or dilution risk, weakening its ability to withstand prolonged revenue or margin setbacks across quarters.
Execution Risk From Manufacturing TransitionOperational disruptions have already depressed shipments, absorption and margins; such transitions can continue to cause timing delays, backlog and higher per-unit costs. Ongoing execution risk threatens near-to-medium term revenue recovery, margin restoration and could extend cash burn while customer relationships are tested.
Lifeward News
LFWD FAQ
What was Lifeward’s price range in the past 12 months?
Lifeward lowest stock price was $4.14 and its highest was $10.98 in the past 12 months.
What is Lifeward’s market cap?
Lifeward’s market cap is $21.64M.
When is Lifeward’s upcoming earnings report date?
Lifeward’s upcoming earnings report date is Aug 12, 2026 which is in 40 days.
How were Lifeward’s earnings last quarter?
Lifeward released its earnings results on May 15, 2026. The company reported -$3.13 earnings per share for the quarter, missing the consensus estimate of -$1.18 by -$1.95.
Is Lifeward overvalued?
According to Wall Street analysts Lifeward’s price is currently Undervalued.
Does Lifeward pay dividends?
Lifeward does not currently pay dividends.
What is Lifeward’s EPS estimate?
Lifeward’s EPS estimate is -1.39.
How many shares outstanding does Lifeward have?
Lifeward has 2,814,409 shares outstanding.
What happened to Lifeward’s price movement after its last earnings report?
Lifeward reported an EPS of -$3.13 in its last earnings report, missing expectations of -$1.18. Following the earnings report the stock price went up 1.592%.
Which hedge fund is a major shareholder of Lifeward?
Currently, no hedge funds are holding shares in LFWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lifeward
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
LFWD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.View all LFWD earnings summariesLFWD Stock 12 Month Forecast
Average Price Target
$10.00
▲(47.28% Upside)
Technical Analysis
Ownership Overview
29.44% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
70.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---